Profile data is unavailable for this security.
About the company
Nightingale Health Oyj is a Finland-based health technology company that aims to promote preventative health and help people stay healthy. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The Company provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Company’s subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The Company owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.
- Revenue in EUR (TTM)3.65m
- Net income in EUR-18.06m
- Incorporated2002
- Employees81.00
- LocationNightingale Health OyjMannerheimintie 164aHELSINKI 00300FinlandFIN
- Phone+358 207301810
- Websitehttps://nightingalehealth.com/
More ▼
Mergers & acquisitions
| Acquired company | HEALTH:HEX since announced | Transaction value |
|---|---|---|
| Welltus Inc | 66.36% | -- |
Data delayed at least 15 minutes, as of Jun 07 2024 10:35 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bergenbio ASA | 45.37k | -13.46m | 48.23m | 16.00 | -- | 408.26 | -- | 1,063.08 | -0.1849 | -0.1849 | 0.0003 | 0.0347 | 0.0047 | -- | 0.0485 | 20,840.00 | -139.81 | -66.15 | -275.19 | -78.74 | -- | -- | -29,658.54 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Enzymatica AB (publ) | 4.18m | -4.74m | 48.41m | 18.00 | -- | 6.53 | -- | 11.59 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Promimic AB | 3.49m | -828.71k | 53.25m | 17.00 | -- | 8.26 | -- | 15.24 | -0.5067 | -0.5067 | 2.14 | 3.91 | 0.4533 | -4.61 | 5.46 | 2,325,471.00 | -10.75 | -24.89 | -12.43 | -29.25 | 104.25 | 101.23 | -23.73 | -89.47 | 4.13 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -2.35m | 55.32m | 7.00 | -- | 13.83 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Gentian Diagnostics ASA | 12.38m | -507.93k | 57.48m | 58.00 | -- | 4.36 | 184.38 | 4.64 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Oncopeptides AB | 3.46m | -21.72m | 59.67m | 62.00 | -- | -- | -- | 17.24 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Orexo AB | 54.70m | -6.49m | 61.34m | 113.00 | -- | 11.22 | 119.69 | 1.12 | -2.13 | -2.13 | 17.98 | 1.78 | 0.6959 | 1.08 | 2.53 | 5,337,069.00 | -8.25 | -6.41 | -20.27 | -9.99 | 88.14 | 86.76 | -11.86 | -11.83 | 0.589 | 0.1386 | 0.8948 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Moberg Pharma AB (publ) | 72.45k | -1.99m | 64.01m | 9.00 | -- | 1.18 | -- | 883.40 | -1.09 | -1.09 | 0.0379 | 21.63 | 0.0014 | -- | 0.2841 | -- | -3.81 | -- | -3.96 | -- | 60.00 | -- | -2,751.22 | -- | 1.73 | -- | 0.0073 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| Intellego Technologies AB | 16.48m | 5.27m | 67.53m | 62.00 | 12.44 | 5.05 | 12.11 | 4.10 | 2.33 | 2.33 | 7.35 | 5.74 | 0.8841 | 3.87 | 3.69 | 3,007,968.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 2.07 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Nightingale Health Oyj | 3.65m | -18.06m | 67.87m | 81.00 | -- | 1.16 | -- | 18.58 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| IRLAB Therapeutics AB | 501.70k | -13.90m | 71.38m | 28.00 | -- | 10.54 | -- | 142.29 | -3.03 | -3.03 | 0.1095 | 1.48 | 0.0274 | -- | 0.4652 | 218,384.60 | -75.97 | -27.12 | -94.23 | -30.42 | -1,952.47 | -72.18 | -2,770.38 | -155.57 | -- | -- | 0.2646 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Alligator Bioscience AB | 4.90m | -21.98m | 72.20m | 55.00 | -- | -- | -- | 14.73 | -0.4848 | -0.4848 | 0.0999 | -0.0772 | 0.5289 | -- | 8.07 | 956,741.40 | -237.13 | -73.26 | -- | -91.33 | -- | -- | -448.35 | -811.68 | -- | -104.20 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Cantargia AB | 0.00 | -21.30m | 77.90m | 23.00 | -- | 6.63 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7239 | 0.00 | -- | -- | 0.00 | -83.14 | -55.08 | -107.52 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Vistin Pharma ASA | 38.17m | 4.90m | 84.95m | 77.00 | 17.35 | 3.28 | 13.17 | 2.23 | 1.27 | 1.27 | 9.88 | 6.70 | 1.11 | 2.31 | 7.44 | 5,692,663.00 | 14.28 | 1.73 | 18.93 | 2.11 | 59.93 | 58.92 | 12.83 | 2.36 | 0.8536 | 32.96 | 0.0934 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
| BioPorto A/S | 4.34m | -7.21m | 84.99m | 27.00 | -- | 15.20 | -- | 19.58 | -0.1501 | -0.1501 | 0.0903 | 0.1099 | 0.4132 | 3.66 | 7.33 | 1,044,452.00 | -68.68 | -71.10 | -100.20 | -96.55 | 68.08 | 63.38 | -166.23 | -239.22 | 2.36 | -- | 0.1354 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
Data as of Jun 07 2024. Currency figures normalised to Nightingale Health Oyj's reporting currency: Euro EUR
11.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nordea Investment Management AB (Finland)as of 29 Feb 2024 | 1.90m | 4.83% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 1.06m | 2.70% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 793.40k | 2.02% |
| Sp-Fund Management Co. Ltd.as of 30 Apr 2024 | 475.74k | 1.21% |
| Kieger AGas of 31 Mar 2023 | 150.00k | 0.38% |
| S-Bank Fund Management Ltd.as of 31 Dec 2023 | 0.00 | 0.00% |
| DNCA Finance SAas of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2023 - 29 May 2024Source: FactSet Research Systems Inc.
